8. COMMITMENTS AND CONTINGENCIES

Operating Lease Commitment

Sublease Commitment

Effective August 26, 2021, the Company entered into a sublease agreement with a third party to sublease 12,112 square feet of the 30,023 square feet currently being leased under one of its two existing lease agreements. The sublease commenced on October 1, 2021 and ends October 31, 2026. The Company notes sublease income of $55,133 and $0 was recognized and offset against rent expense for the three months ended March 31, 2022 and 2021, respectively.

Legal Proceedings

On November 18, 2021, Venn Therapeutics, LLC (“Venn”), filed a complaint (the “Complaint”) against the Company in the U.S. District Court for the Middle District of Florida. The Complaint asserts claims for trade secret misappropriation under federal law and state law, a claim for breach of contract, and state law claims for unfair competition, misrepresentation, unjust enrichment, and intentional interference with advantageous business relations. On November 24, 2021, Venn filed a motion for a preliminary injunction, which requests that the court preliminarily enjoin the Company from using Venn’s trade secrets and/or confidential information without Venn’s consent, including by conducting any further development work of our immunotherapy program based on CRB-601, until further order of the court. The Company filed a motion to dismiss the Complaint in its entirety and an opposition to Venn’s motion for a preliminary injunction.

Venn filed an amended complaint (the “Amended Complaint”) against the Company, its Chief Executive Officer, Dr. Yuval Cohen, and a former Corbus employee, on April 6, 2022. The Company filed a motion to dismiss the complaint in its entirety on May 6, 2022.

We believe that the Amended Complaint and Venn’s preliminary injunction motion are without merit and intend to vigorously defend the Company against these claims; however, there can be no assurance that we will prevail in such proceedings.